ContextVision Annual General Meeting

On the 6th of May 2020, ContextVision held its ordinary Shareholders' Annual General Meeting in Stockholm.

• The annual financial report regarding 2019 was presented and approved by the AGM.
• Disposition of financial results according to the proposal of the Board of Directors was approved.
• The Managing Director and the Board of Directors were discharged from liability.
• The proposed guidelines for remuneration to the Board of Directors and senior executives was approved.
• Board compensation was decided according to the following:
  • The chairman of the board will be paid SEK 300.000 for the period until next AGM.
  • Other members of the board, whom are not also main shareholders, will be paid SEK 200.000 for the period until next AGM.
• The audit fee will be based on current account.
• Erik Danielsen, Martin Hedlund, Sven Günther-Hanssen and Magne Jordanger were reelected as board members. Martin Ingvar was elected as new member of the board.
• No deputy members were elected.
• Ernst & Young were reelected as auditor for the coming year, with acting auditor Andreas Troberg.
• No other matters were processed at the meeting.

For further information, please contact:
Ann-Charlotte Linderoth (CFO) tel +46 (0)8 7503550, e-mail ann-charlotte.linderoth@contextvision.se

###

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

###

About ContextVision

ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.

ContextVision is now entering the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.